Theranexus announces a fundraising round of 3.1 million euros
July 18, 2023
News
Theranexus, an innovative biopharmaceutical company in the treatment of rare neurological diseases, which has gone through the ranks of IncubAlliance, announces a fundraising of 3.1 million euros.
A spin-off from the CEA (French Alternative Energies and Atomic Energy Commission), specializing in the treatment of rare neurological diseases and a pioneer in the development of drug candidates targeting both neurons and glial cells, Theranexus has come a long way since its graduation from IncubAlliance. Listed on the Euronext Growth market in Paris, the company today announced the completion of a €3.1 million funding round, of which approximately €2.5 million was subscribed by specialized and strategic investors through an accelerated book-building process, and €0.6 million by individual investors via the PrimaryBid platform.
Currently possessing a unique platform for identifying and characterizing innovative therapy drug candidates in the field of rare neurological disorders, and with its first drug candidate in clinical development for Batten disease, Theranexus intends to accelerate its growth with this fundraising round. Combined with the company's existing funds, the proceeds from this round will contribute to financing the pivotal Phase 3 trial of the drug candidate Batten-1, designed to treat pediatric patients with Batten disease, a rare neurological disorder. This Phase 3 trial is expected to begin at the end of the second half of 2023 and conclude at the end of 2026, with estimated costs of €5 million per year for three years. The funds raised will also be used to finance the company's other research and development activities, as well as its general operating needs.
«We thank all our investors and new shareholders for their trust and commitment to this transaction. We also wish to acknowledge the participation of the BBDF Foundation, which has renewed its confidence in our ability to successfully develop Batten-1 to provide a therapeutic solution for patients with Batten disease. We are also delighted by the participation of individual investors through the PrimaryBid platform. Thanks to the validation of the Phase 3 design, the encouraging preliminary Phase I/II results, and the success of this transaction, we will launch the pivotal Phase 3 trial of Batten-1 by the end of 2023. We are aiming for its approval and commercialization by 2027, which would make Batten-1 the first approved product for Batten disease worldwide.», concludes Mathieu Charvériat, CEO of Theranexus.
To learn more about Theranexus: https://www.theranexus.com/fr/